{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,16]],"date-time":"2026-04-16T08:03:21Z","timestamp":1776326601341,"version":"3.50.1"},"update-to":[{"DOI":"10.1002\/14651858.cd012429","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2025,1,20]],"date-time":"2025-01-20T00:00:00Z","timestamp":1737331200000}}],"reference-count":76,"publisher":"Wiley","issue":"1","content-domain":{"domain":["wiley.com","cochranelibrary.com"],"crossmark-restriction":true},"short-container-title":[],"DOI":"10.1002\/14651858.cd012429.pub2","type":"journal-article","created":{"date-parts":[[2025,1,20]],"date-time":"2025-01-20T06:42:38Z","timestamp":1737355358000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Lurasidone versus typical antipsychotics for schizophrenia"],"prefix":"10.1002","volume":"2025","author":[{"given":"Dawid","family":"Storman","sequence":"additional","affiliation":[{"name":"Chair of Epidemiology and Preventive Medicine, Department of Hygiene and Dietetics; Jagiellonian University Medical College; Krakow Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Magdalena","family":"Koperny","sequence":"additional","affiliation":[{"name":"Chair of Epidemiology and Preventive Medicine, Department of Epidemiology; Jagiellonian University Medical College; Krakow Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Krzysztof","family":"Stycze\u00f1","sequence":"additional","affiliation":[{"name":"Section of Affective Disorders, Department of Psychiatry; Jagiellonian University Medical College; Krakow Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wojciech","family":"Datka","sequence":"additional","affiliation":[{"name":"Section of Affective Disorders, Department of Psychiatry; Jagiellonian University Medical College; Krakow Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rafal R","family":"Jaeschke","sequence":"additional","affiliation":[{"name":"Section of Affective Disorders, Department of Psychiatry; Jagiellonian University Medical College; Krakow Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2025,1,20]]},"reference":[{"key":"10.1002\/14651858.CD012429.pub2-BIB0001|cit1","unstructured":"Lurasidone effects on tissue glutamate in schizophrenia https:\/\/www.clinicalTrials.gov\/ct\/show\/NCT02199743"},{"issue":"6","key":"10.1002\/14651858.CD012429.pub2-BIB0002|cit2","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1177\/2045125315621242","article-title":"Corrigendum","volume":"5","year":"2015","journal-title":"Therapeutic Advances in Psychopharmacology"},{"key":"10.1002\/14651858.CD012429.pub2-BIB0003|cit3","unstructured":"A 6-week, double-blind, randomized, fixed-dose, parallel-group study of the efficacy and safety of three dose levels of SM-13496 compared to placebo and haloperidol in patients with schizophrenia who are experiencing an acute exacerbation of symptoms https:\/\/www.ClinicalTrials.gov\/ct\/show\/NCT00044044"},{"issue":"6","key":"10.1002\/14651858.CD012429.pub2-BIB0004|cit4","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1177\/2045125315606027","article-title":"A 6-week, double-blind, placebo- and haloperidol-controlled, phase II study of lurasidone in patients with acute schizophrenia","volume":"5","author":"Potkin","year":"2015","journal-title":"Therapeutic Advances in Psychopharmacology"},{"key":"10.1002\/14651858.CD012429.pub2-BIB0005|cit5","doi-asserted-by":"crossref","unstructured":"Australian Prescriber Editorial Executive Committee Lurasidone https:\/\/australianprescriber.tg.org.au\/articles\/lurasidone-for-schizophrenia.html 39 1 25 6 10.18773\/austprescr.2016.001","DOI":"10.18773\/austprescr.2016.001"},{"key":"10.1002\/14651858.CD012429.pub2-BIB0006|cit6","unstructured":"TAILOR - an experimental study comparing discontinuation with maintenance therapy of antipsychotic medication in patients with newly diagnosed schizophrenia or schizophrenia-like psychosis without psychotic symptoms www.clinicaltrialsregister.eu\/ctr-search\/trial\/2016-000565-23\/DK"},{"key":"10.1002\/14651858.CD012429.pub2-BIB0007|cit7","doi-asserted-by":"crossref","first-page":"S149","DOI":"10.1016\/S0920-9964(14)70445-1","article-title":"Is quality of life related to cognitive performance or negative symptoms in patients with schizophrenia? Results from a double-blind, active-controlled, lurasidone continuation study","volume":"153","author":"Harvey","year":"2014","journal-title":"Schizophrenia Research"},{"key":"10.1002\/14651858.CD012429.pub2-BIB0008|cit8","first-page":"S515","article-title":"Is quality of life related to cognitive performance or negative symptoms in patients with schizophrenia? Results from a double-blind, active-controlled, lurasidone extension study","volume":"38","author":"Harvey","year":"2013","journal-title":"Neuropsychopharmacology"},{"key":"10.1002\/14651858.CD012429.pub2-BIB0009|cit9","doi-asserted-by":"crossref","first-page":"S351","DOI":"10.1016\/S0920-9964(12)71029-0","article-title":"Long-term treatment with lurasidone in schizophrenia: results of an 8-week double-blind acute study followed by a 44-week open-label extension","volume":"136","author":"Kato","year":"2012","journal-title":"Schizophrenia Research"},{"key":"10.1002\/14651858.CD012429.pub2-BIB0010|cit10","unstructured":"Lurasidone HCl a phase 3 study of patients with acute schizophrenia https:\/\/clinicaltrials.gov\/show\/NCT00615433"},{"key":"10.1002\/14651858.CD012429.pub2-BIB0011|cit11","unstructured":"Lurasidone HCl - a long term safety phase 3 study of patients with clinically stable schizophrenia https:\/\/clinicaltrials.gov\/show\/NCT00641745"},{"key":"10.1002\/14651858.CD012429.pub2-BIB0012|cit12","unstructured":"Study of SM-13496 (lurasidone HCl) in patients With schizophrenia https:\/\/clinicaltrials.gov\/show\/NCT00711269"},{"key":"10.1002\/14651858.CD012429.pub2-BIB0013|cit13","unstructured":"Lurasidone HCl - a long term phase 3 study of patients with chronic schizophrenia https:\/\/clinicaltrials.gov\/show\/NCT00789698"},{"key":"10.1002\/14651858.CD012429.pub2-BIB0014|cit14","unstructured":"Lurasidone HCL - a 6-week phase 3 study of patients with acute schizophrenia https:\/\/clinicaltrials.gov\/ct2\/show\/NCT00790192"},{"key":"10.1002\/14651858.CD012429.pub2-BIB0015|cit15","unstructured":"Lurasidone extended use study https:\/\/clinicaltrials.gov\/show\/NCT01485640"},{"key":"10.1002\/14651858.CD012429.pub2-BIB0016|cit16","unstructured":"High dose lurasidone for patients with treatment resistant schizophrenia https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01569659"},{"key":"10.1002\/14651858.CD012429.pub2-BIB0017|cit17","unstructured":"A phase III study of SM-13496 (lurasidone HCl) in patients with schizophrenia https:\/\/clinicaltrials.gov\/show\/NCT01614899"},{"key":"10.1002\/14651858.CD012429.pub2-BIB0018|cit18","unstructured":"Long-term extension study of SM-13496 (lurasidone HCl) in patients with schizophrenia https:\/\/clinicaltrials.gov\/show\/NCT01614912"},{"key":"10.1002\/14651858.CD012429.pub2-BIB0019|cit19","unstructured":"A clinical trial of lurasidone in treatment of schizophrenia https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02002832"},{"key":"10.1002\/14651858.CD012429.pub2-BIB0020|cit20","unstructured":"A study of lurasidone HCl in subjects with schizophrenia https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03393026"},{"key":"10.1002\/14651858.CD012429.pub2-BIB0021|cit21","unstructured":"A 6-week study to evaluate the efficacy and safety of lurasidone HCL in acutely psychotic patients With schizophrenia https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03465787"},{"issue":"5","key":"10.1002\/14651858.CD012429.pub2-BIB0022|cit22","doi-asserted-by":"publisher","first-page":"342","DOI":"10.3109\/01612840.2012.669025","article-title":"Lurasidone (Latuda R): an atypical antipsychotic","volume":"33","author":"Nolan","year":"2012","journal-title":"Issues in Mental Health Nursing"},{"key":"10.1002\/14651858.CD012429.pub2-BIB0023|cit23","unstructured":"Lurasidone (Latuda) for schizophrenia medicalletter.org\/TML-article-1358a 1358"},{"issue":"11","key":"10.1002\/14651858.CD012429.pub2-BIB0024|cit24","doi-asserted-by":"publisher","first-page":"937","DOI":"10.5498\/wjp.v13.i11.937","article-title":"Safety and effectiveness of lurasidone in the treatment of Chinese schizophrenia patients: an interim analysis of post-marketing surveillance","volume":"13","author":"Wei","year":"2023","journal-title":"World Journal of Psychiatry"},{"key":"10.1002\/14651858.CD012429.pub2-BIB0025|cit25","doi-asserted-by":"crossref","first-page":"S278","DOI":"10.1016\/S0920-9964(12)70827-7","article-title":"Effect of lurasidone on weight and metabolic parameters: a comprehensive database analysis","volume":"136","author":"Pikalov","year":"2012","journal-title":"Schizophrenia Research"},{"issue":"5","key":"10.1002\/14651858.CD012429.pub2-BIB0026|cit26","doi-asserted-by":"crossref","first-page":"417","DOI":"10.3109\/09540261.2010.515205","article-title":"Sex differences in schizophrenia","volume":"22","author":"Abel","year":"2010","journal-title":"International Review of Psychiatry"},{"issue":"1","key":"10.1002\/14651858.CD012429.pub2-BIB0027|cit27","doi-asserted-by":"publisher","first-page":"75","DOI":"10.4088\/JCP.09m05258gre","article-title":"Impact of second-generation antipsychotics and perphenazine on depressive symptoms in a randomized trial of treatment for chronic schizophrenia","volume":"72","author":"Addington","year":"2011","journal-title":"Journal of Clinical Psychiatry"},{"issue":"4","key":"10.1002\/14651858.CD012429.pub2-BIB0028|cit28","first-page":"405","article-title":"The problem of therapeutic efficacy indices. 3. Comparison of the indices and their use","volume":"54","author":"Boissel","year":"1999","journal-title":"Therapie"},{"issue":"2","key":"10.1002\/14651858.CD012429.pub2-BIB0029|cit29","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1002\/wps.20204","article-title":"Effects of antipsychotics, antidepressants and mood stabilizers on risk for physical diseases in people with schizophrenia, depression and bipolar disorder","volume":"14","author":"Correll","year":"2015","journal-title":"World Psychiatry"},{"issue":"6","key":"10.1002\/14651858.CD012429.pub2-BIB0030|cit30","doi-asserted-by":"publisher","first-page":"1087","DOI":"10.12740\/PP\/37438","article-title":"The association between cognitive deficits and different outcomes of schizophrenia","volume":"48","author":"De Nijs","year":"2014","journal-title":"Psychiatria Polska"},{"key":"10.1002\/14651858.CD012429.pub2-BIB0031|cit31","unstructured":"Deeks J Issues in the selection for meta-analyses of binary data 8th International Cochrane Colloquium; 2000 Oct 25-28; Cape Town Cape Town The Cochrane Collaboration 2000"},{"key":"10.1002\/14651858.CD012429.pub2-BIB0032|cit32","doi-asserted-by":"crossref","DOI":"10.1176\/appi.books.9780890425596","volume-title":"Diagnostic and Statistical Manual of Mental Disorders","author":"American Psychiatric Association","year":"2013"},{"issue":"5","key":"10.1002\/14651858.CD012429.pub2-BIB0033|cit33","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1185\/030079908X291958","article-title":"The clinical relevance of changes in the Montgomery-Asberg Depression Rating Scale using the minimum clinically important difference approach","volume":"24","author":"Duru","year":"2008","journal-title":"Current Medical Research and Opinion"},{"key":"10.1002\/14651858.CD012429.pub2-BIB0034|cit34","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1136\/bmj.315.7109.629","article-title":"Bias in meta-analysis detected by a simple, graphical test","volume":"315","author":"Egger","year":"1997","journal-title":"BMJ"},{"key":"10.1002\/14651858.CD012429.pub2-BIB0035|cit35","unstructured":"Latuda (lurasidone hydrochloride) tablets www.accessdata.fda.gov\/drugsatfda_docs\/label\/2013\/200603lbls10s11.pdf"},{"issue":"10","key":"10.1002\/14651858.CD012429.pub2-BIB0036|cit36","doi-asserted-by":"publisher","first-page":"1115","DOI":"10.1001\/ARCHPSYC.64.10.1115","article-title":"Cognitive improvement after treatment with second-generation antipsychotic medications in first-episode schizophrenia: is it a practice effect?","volume":"64","author":"Goldberg","year":"2007","journal-title":"Archives of General Psychiatry"},{"issue":"2","key":"10.1002\/14651858.CD012429.pub2-BIB0037|cit37","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1176\/APPI.AJP.163.2.185","article-title":"Why olanzapine beats risperidone, risperidone beats quetiapine, and quetiapine beats olanzapine: an exploratory analysis of head-to-head comparison studies of second-generation antipsychotics","volume":"163","author":"Heres","year":"2006","journal-title":"American Journal of Psychiatry"},{"issue":"4","key":"10.1002\/14651858.CD012429.pub2-BIB0038|cit38","first-page":"11983","article-title":"Minimum clinically important difference in the Positive and Negative Syndrome Scale with data from the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE)","volume":"73","author":"Hermes","year":"2012","journal-title":"Journal of Clinical Psychiatry"},{"key":"10.1002\/14651858.CD012429.pub2-BIB0039|cit39","unstructured":"Higgins JPT Green S Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011 Available from www.training.cochrane.org\/handbook\/archives\/v5.1"},{"key":"10.1002\/14651858.CD012429.pub2-BIB0040|cit40","unstructured":"Higgins JPT Thomas J Chandler J Cumpston M Li T Page MJ Cochrane Handbook for Systematic Reviews of Interventions version 6.5. Cochrane, 2024 Available from training.cochrane.org\/handbook"},{"issue":"9929","key":"10.1002\/14651858.CD012429.pub2-BIB0041|cit41","doi-asserted-by":"crossref","first-page":"1677","DOI":"10.1016\/S0140-6736(13)62036-X","article-title":"Schizophrenia: an integrated sociodevelopmental-cognitive model","volume":"383","author":"Howes","year":"2014","journal-title":"Lancet"},{"key":"10.1002\/14651858.CD012429.pub2-BIB0042|cit42","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1016\/S0140-6736(19)31135-3","article-title":"Comparative efficacy and tolerability of 32 oral antipsychotics for the acute treatment of adults with multi-episode schizophrenia: a systematic review and network meta-analysis","volume":"394","author":"Huhn","year":"2019","journal-title":"Lancet"},{"issue":"7","key":"10.1002\/14651858.CD012429.pub2-BIB0043|cit43","doi-asserted-by":"crossref","first-page":"1598","DOI":"10.1111\/bcp.13945","article-title":"Trends in utilization and dosing of antipsychotic drugs in Scandinavia: comparison of 2006 and 2016","volume":"85","author":"H\u00f8jlund","year":"2019","journal-title":"British Journal of Clinical Pharmacology"},{"issue":"4","key":"10.1002\/14651858.CD012429.pub2-BIB0044|cit44","doi-asserted-by":"publisher","first-page":"748","DOI":"10.1016\/j.pharep.2016.04.002","article-title":"Lurasidone: the 2016 update on the pharmacology, efficacy and safety profile","volume":"68","author":"Jaeschke","year":"2016","journal-title":"Pharmacological Reports"},{"issue":"Suppl 3","key":"10.1002\/14651858.CD012429.pub2-BIB0045|cit45","first-page":"S342","article-title":"Antipsychotics - history of development and field of indication, new wine - old glasses","volume":"24","author":"Jasovic-Gasic","year":"2012","journal-title":"Psychiatria Danubina"},{"issue":"10","key":"10.1002\/14651858.CD012429.pub2-BIB0046|cit46","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1001\/jamapsychiatry.2013.149","article-title":"Comparative mortality risk in adult patients with schizophrenia, depression, bipolar disorder, anxiety disorders, and attention-deficit\/hyperactivity disorder participating in psychopharmacology clinical trials","volume":"70","author":"Khan","year":"2013","journal-title":"JAMA Psychiatry"},{"issue":"10","key":"10.1002\/14651858.CD012429.pub2-BIB0047|cit47","doi-asserted-by":"crossref","first-page":"2318","DOI":"10.1038\/sj.npp.1301147","article-title":"Linking the PANSS, BPRS, and CGI: clinical implications","volume":"31","author":"Leucht","year":"2006","journal-title":"Neuropsychopharmacology"},{"issue":"9896","key":"10.1002\/14651858.CD012429.pub2-BIB0048|cit48","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1016\/S0140-6736(13)60733-3","article-title":"Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis","volume":"382","author":"Leucht","year":"2013","journal-title":"Lancet"},{"issue":"1-3","key":"10.1002\/14651858.CD012429.pub2-BIB0049|cit49","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.schres.2013.01.009","article-title":"Efficacy and safety of lurasidone 80 mg\/day and 160 mg\/day in the treatment of schizophrenia: a randomized, double-blind, placebo- and active-controlled trial","volume":"145","author":"Loebel","year":"2013","journal-title":"Schizophrenia Research"},{"issue":"1","key":"10.1002\/14651858.CD012429.pub2-BIB0050|cit50","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.eurpsy.2014.08.001","article-title":"Efficacy of lurasidone across five symptom dimensions of schizophrenia: pooled analysis of short-term, placebo-controlled studies","volume":"30","author":"Loebel","year":"2015","journal-title":"European Psychiatry"},{"issue":"2","key":"10.1002\/14651858.CD012429.pub2-BIB0051|cit51","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1177\/104012371402600206","article-title":"A current review of cytochrome P450 interactions of psychotropic drugs","volume":"26","author":"Madhusoodanan","year":"2014","journal-title":"Annals of Clinical Psychiatry"},{"issue":"2","key":"10.1002\/14651858.CD012429.pub2-BIB0052|cit52","doi-asserted-by":"crossref","first-page":"170","DOI":"10.4088\/JCP.12m07992","article-title":"Effectiveness of lurasidone in patients with schizophrenia or schizoaffective disorder switched from other antipsychotics: a randomized, six week, open-label study","volume":"74","author":"McEvoy","year":"2013","journal-title":"Journal of Clinical Psychiatry"},{"key":"10.1002\/14651858.CD012429.pub2-BIB0053|cit53","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1093\/epirev\/mxn001","article-title":"Schizophrenia: a concise overview of incidence, prevalence, and mortality","volume":"30","author":"McGrath","year":"2008","journal-title":"Epidemiologic Reviews"},{"issue":"1","key":"10.1002\/14651858.CD012429.pub2-BIB0054|cit54","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.coph.2011.02.007","article-title":"The role of serotonin receptors in the action of atypical antipsychotic drugs","volume":"11","author":"Meltzer","year":"2011","journal-title":"Current Opinion in Pharmacology"},{"issue":"11","key":"10.1002\/14651858.CD012429.pub2-BIB0055|cit55","doi-asserted-by":"crossref","first-page":"1715","DOI":"10.1517\/13543780903286388","article-title":"Lurasidone: a new drug in development for schizophrenia","volume":"18","author":"Meyer","year":"2009","journal-title":"Expert Opinion on Investigational Drugs"},{"issue":"2","key":"10.1002\/14651858.CD012429.pub2-BIB0056|cit56","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1080\/10401230701334606","article-title":"Are there any differences in the efficacy among second generation antipsychotics in the treatment of schizophrenia and related disorders?","volume":"19","author":"Motlov\u00e1","year":"2007","journal-title":"Annals of Clinical Psychiatry"},{"issue":"2","key":"10.1002\/14651858.CD012429.pub2-BIB0057|cit57","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1017\/S1092852914000285","article-title":"Lurasidone for the treatment of depressive symptoms in schizophrenia: analysis of four pooled, six week, placebo-controlled studies","volume":"20","author":"Nasrallah","year":"2015","journal-title":"CNS Spectrums"},{"issue":"9","key":"10.1002\/14651858.CD012429.pub2-BIB0058|cit58","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD011831.pub2","article-title":"Chlorpromazine versus penfluridol for schizophrenia","author":"Nikvarz","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"3","key":"10.1002\/14651858.CD012429.pub2-BIB0059|cit59","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1056\/NEJMoa0806994","article-title":"Atypical antipsychotic drugs and the risk of sudden cardiac death","volume":"360","author":"Ray","year":"2009","journal-title":"New England Journal of Medicine"},{"key":"10.1002\/14651858.CD012429.pub2-BIB0060|cit60","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1146\/annurev.psych.60.110707.163642","article-title":"Social withdrawal in childhood","volume":"60","author":"Rubin","year":"2009","journal-title":"Annual Review of Psychology"},{"issue":"9859","key":"10.1002\/14651858.CD012429.pub2-BIB0061|cit61","doi-asserted-by":"publisher","first-page":"2129","DOI":"10.1016\/S0140-6736(12)61680-8","article-title":"Common values in assessing health outcomes from disease and injury: disability weights measurement study for the Global Burden of Disease Study 2010","volume":"380","author":"Salomon","year":"2012","journal-title":"Lancet"},{"key":"10.1002\/14651858.CD012429.pub2-BIB0062|cit62","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12913-017-2031-8","article-title":"Acceptability of healthcare interventions: an overview of reviews and development of a theoretical framework","volume":"17","author":"Sekhon","year":"2017","journal-title":"BMC Health Services Research"},{"issue":"6","key":"10.1002\/14651858.CD012429.pub2-BIB0063|cit63","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1016\/S0010-440X(99)90082-2","article-title":"A history of antipsychotic drug development","volume":"40","author":"Shen","year":"1999","journal-title":"Comprehensive Psychiatry"},{"issue":"4","key":"10.1002\/14651858.CD012429.pub2-BIB0064|cit64","doi-asserted-by":"publisher","first-page":"209","DOI":"10.15171\/bi.2017.25","article-title":"Study-based registers of randomized controlled trials: starting a systematic review with data extraction or meta-analysis","volume":"7","author":"Shokraneh","year":"2017","journal-title":"BioImpacts"},{"key":"10.1002\/14651858.CD012429.pub2-BIB0065|cit65","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1186\/s13643-019-1035-3","article-title":"Study-based registers reduce waste in systematic reviewing: discussion and case report","volume":"8","author":"Shokraneh","year":"2019","journal-title":"Systematic Reviews"},{"issue":"4","key":"10.1002\/14651858.CD012429.pub2-BIB0066|cit66","doi-asserted-by":"publisher","first-page":"e002808","DOI":"10.1136\/bmjopen-2013-002808","article-title":"Schizophrenia is associated with excess multiple physical-health comorbidities but low levels of recorded cardiovascular disease in primary care: cross-sectional study","volume":"3","author":"Smith","year":"2013","journal-title":"BMJ Open"},{"key":"10.1002\/14651858.CD012429.pub2-BIB0067|cit67","doi-asserted-by":"publisher","first-page":"5571","DOI":"10.1038\/s41598-021-84836-z","article-title":"A network meta-analysis of the dose\u2013response effects of lurasidone on acute schizophrenia","volume":"11","author":"Srisurapanont","year":"2021","journal-title":"Scientific Reports"},{"issue":"5","key":"10.1002\/14651858.CD012429.pub2-BIB0068|cit68","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD007815.pub2","article-title":"Quetiapine versus typical antipsychotic medications for schizophrenia","author":"Suttajit","year":"2013","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"9","key":"10.1002\/14651858.CD012429.pub2-BIB0069|cit69","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1007\/s00127-013-0651-9","article-title":"Annual incidence rate of schizophrenia and schizophrenia spectrum disorders in a longitudinal population-based cohort study","volume":"48","author":"Sutterland","year":"2013","journal-title":"Social Psychiatry and Psychiatric Epidemiology"},{"issue":"6","key":"10.1002\/14651858.CD012429.pub2-BIB0070|cit70","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1111\/acps.12343","article-title":"Comparative efficacy and acceptability of drug treatments for bipolar depression: a multiple-treatments meta-analysis","volume":"130","author":"Taylor","year":"2014","journal-title":"Acta Psychiatrica Scandinavica"},{"issue":"1","key":"10.1002\/14651858.CD012429.pub2-BIB0071|cit71","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.bbr.2007.12.006","article-title":"Cognitive dysfunction in neuropsychiatric disorders: selected serotonin receptor subtypes as therapeutic targets","volume":"195","author":"Terry","year":"2008","journal-title":"Behavioural Brain Research"},{"key":"10.1002\/14651858.CD012429.pub2-BIB0072|cit72","first-page":"129\u201333","article-title":"Global burden of disease - summary of 2010 GBD study","volume":"7","author":"Top\u00f3r\u2011M\u0105dry","year":"2013","journal-title":"Medycyna Praktyczna"},{"key":"10.1002\/14651858.CD012429.pub2-BIB0073|cit73","unstructured":"WHO Model List of Essential Medicines 2019 https:\/\/apps.who.int\/iris\/bitstream\/handle\/10665\/325771\/WHO-MVP-EMP-IAU-2019.06-eng.pdf"},{"issue":"1","key":"10.1002\/14651858.CD012429.pub2-BIB0074|cit74","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1093\/oxfordjournals.schbul.a033315","article-title":"Natural course of schizophrenic disorders: a 15-year followup of a Dutch incidence cohort","volume":"24","author":"Wiersma","year":"1998","journal-title":"Schizophrenia Bulletin"},{"key":"10.1002\/14651858.CD012429.pub2-BIB0075|cit75","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1016\/j.jpsychires.2018.06.005","article-title":"Short-term efficacy and tolerability of lurasidone in the treatment of acute schizophrenia: a meta-analysis of randomized controlled trials","volume":"103","author":"Zheng","year":"2018","journal-title":"Journal of Psychiatric Research"},{"issue":"11","key":"10.1002\/14651858.CD012429.pub2-BIB0076|cit76","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD012429","article-title":"Lurasidone versus typical antipsychotics for schizophrenia","author":"Datka","year":"2016","journal-title":"Cochrane Database of Systematic Reviews"}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","deposited":{"date-parts":[[2026,4,16]],"date-time":"2026-04-16T07:33:30Z","timestamp":1776324810000},"score":1,"resource":{"primary":{"URL":"http:\/\/doi.wiley.com\/10.1002\/14651858.CD012429.pub2"}},"subtitle":[],"editor":[{"name":"Cochrane Central Editorial Service","sequence":"first","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2025,1,20]]},"references-count":76,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,1]]}},"URL":"https:\/\/doi.org\/10.1002\/14651858.cd012429.pub2","relation":{},"ISSN":["1465-1858"],"issn-type":[{"value":"1465-1858","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,20]]}}}